INDIANAPOLIS, Oct. 23, 2025 /PRNewswire/ — IMG (International Medical Group) is excited to announce the winners of its ninth annual Leave Your Mark Grant. This year, more than 4,000 organizations and individuals submitted entries, making it the largest applicant pool in the history of the grant. The two winning organizations are Holistic Ministry of Children of the Horn of Africa (HMCHA) and Yellow Boat of Hope Foundation Indonesia, each receiving $3,500. The three winning individuals are Megan Parham, Joe Charles, and Martin France, each receiving $1,000.

HMCHA is a faith-based organization that helps children in Ethiopia rise out of poverty through education and mentoring. Through its child sponsorship program, HMCHA’s mission is to help students in the Oromia region graduate, support their own families, and contribute to society.

“We are honored and deeply grateful to be a recipient of IMG’s Leave Your Mark Grant,” said Carol Pfleiderer, HMCHA’s Sponsor Coordinator. “This generous support enables us to expand our reach by training more teachers and equipping schools in Oromia with essential resources like solar lights, books, and bookcases. It’s a meaningful investment in the future of children who are striving to rise out of poverty.”

Yellow Boat of Hope Foundation Indonesia is a non-profit organization committed to bridging access to education and basic needs for families living in some of Indonesia’s most remote islands and coastal areas. By providing school boats and clean water solutions, the organization helps children reach school safely and supports communities in building healthier, more sustainable futures.

“We are so excited to have been chosen for the Leave Your Mark Grant,” said Meralda Adam, Chairperson at Yellow Boat of Hope Foundation Indonesia. “These funds will allow us to provide a school boat in a remote coastal village, ensuring children no longer risk their lives paddling unsafe sampans to reach school. We will also be able to install 20 water filters in area households and provide essential educational materials to children, such as books and uniforms.”

The three individual Leave Your Mark winners support a wide range of mission and social good organizations working around the world. This year’s winners will use their grant funds to support initiatives including church planting and well-digging in Kenya, bridge construction for students in Panama, and volunteer-led building projects across the developing world that promote education, public health, and women’s empowerment.

“For the ninth year, we’re honored to recognize individuals and organizations who are making a lasting impact through mission and social good work,” said Justin Poehler, IMG Chief Commercial Officer. “This year’s Leave Your Mark Grant recipients exemplify the spirit of service by working to bring clean water, safe transportation, education, and infrastructure to communities in need around the world.”

IMG has insured mission and social good organizations since the early 1990s, providing key benefits and assistance services for thousands of customers who serve or volunteer internationally. The Leave Your Mark program was launched in 2017 to give back to organizations with charitable missions.

About IMG^® (International Medical Group^®)
IMG^® (International Medical Group^®), a SiriusPoint company, is an award-winning global insurance benefits and assistance services company that has served millions of members worldwide since its founding in 1990. The preeminent provider of travel and health safety solutions, IMG offers a wide range of insurance programs, including international private medical insurance, travel medical insurance, and travel insurance, as well as enterprise services, including insurance administrative services and 24/7 emergency medical, security, and travel assistance. IMG’s world-class services, combined with an extensive product portfolio, provide Global Peace of Mind^® for travelers, students, missionaries, marine crews, and other individuals or groups traveling, working, or living away from home. For more information, please visit www.imglobal.com.

Media Contact: Carly Kessler, IMG Communications Manager, carly.kessler@imglobal.com

PANAMA CITY, Oct. 23, 2025 /PRNewswire/ — BingX, a leading cryptocurrency exchange and Web3 AI company, is excited to announce a new campaign offering zero-fee spot trading for BTC, ETH and BNB, with additional daily rewards for the most active traders.

From October 22 to November 21, 2025, all users trading BTC, ETH, and BNB spot enjoy 0 trading fee benefits, covering BTC/USDT, BTC/USDC, ETH/USDT, ETH/USDC, BNB/USDT, and BNB/USDC trading pairs. In addition, active users who trade the 3 cryptos have a chance to win 100% off rebates on their buying orders based on their ranks among all participants, sequenced by transaction completion time in chronological order. With the offers and rewards, BingX aims to encourage user engagement in the current market trends and capture potential opportunities when they occur.

“It is our commitment to helping our users to grow and achieve their goals,” said Vivien Lin, Chief Product Officer at BingX. “BingX is proud to serve beyond the role of a trading platform by actively catering to the needs of our users and strengthening community engagement.”

The campaign amplifies BingX’s mission in making crypto accessible and friendly to all, by providing timely, relevant opportunities to its users. Leveraging its recent milestones in AI, security and community connection, BingX is building its ecosystem where users can thrive in the latest market evolution.

About BingX

Founded in 2018, BingX is a leading crypto exchange and Web3 AI company, serving a global community of over 20 million users. With a comprehensive suite of AI-powered products and services, including derivatives, spot trading, and copy trading, BingX caters to the evolving needs of users across all experience levels, from beginners to professionals. Committed to building a trustworthy and intelligent trading platform, BingX empowers users with innovative tools designed to enhance performance and confidence. In 2024, BingX proudly became the official crypto exchange partner of Chelsea Football Club, marking an exciting debut in the world of sports sponsorship.

For more information, please visit: https://bingx.com/

BEIJING, Oct. 23, 2025 /PRNewswire/ — SANY Group, a leading construction machinery manufacturer, announced that its self-developed Aerial Water Jet Fire Truck JP100 set a Guinness World Record™ for “The Highest Water Jet from a Fire Truck (Prototype)” with a maximum jet height of 159.66 meters at the 21st China International Fire Protection Equipment Technology Conference & Exposition, which concluded on October 16. This certification marks a historic milestone for SANY’s emergency rescue equipment, and for high-rise buildings firefighting worldwide.

Innovation That Reaches New Heights

As the world’s first 5-axle Aerial Water Jet Fire Truck with a 100-meter boom, the JP100 integrates a range of groundbreaking designs:

• Pioneering boom design combining six telescopic and three folding sections, achieving a 100-meter operational height.
• High- and low-pressure multi-stage centrifugal pump with a rated flow of 50 L/s, delivering a maximum range of over 70 meters and an operational radius exceeding 100 meters.
• Innovative five-axle chassis, 10 tons lighter and one axle fewer than comparable models, ensuring outstanding maneuverability.
• Integrated remote-control system enabling a single operator to perform all key firefighting actions, dramatically improving response efficiency.

Record-Breaking Innovation for Real-World Needs

As urban buildings grow ever taller, high-rise fires have become a global challenge. The record-setting JP100 offers a powerful solution to the difficulty.

• The record-breaking 159.66-meter jet height meets firefighting needs for nearly all super high-rise.
• Flexible articulated boom enables cross-obstacle operations and back-side firefighting for residential buildings of 20-30 stories, largely reducing site constraints.
• A lighter total weight of 54 tons allows rapid response without overloading, and the 23.7-meter turning diameter offers excellent maneuverability in complex urban spaces.

This record is not just a milestone, but a new beginning for SANY in the emergency rescue equipment sector. For years, SANY has paid close attention to innovation, investing about 5% of its sales revenue in R&D annually to build leading product strength and core competitiveness. In its 2025 Tech Festival, SANY even offered over RMB 600 million awards to encourage bold ideas and cutting-edge technologies that redefined the industry.

With the JP100’s record-setting achievement, SANY once again proves that innovation knows no limits—and neither does SANY.

LEHI, Utah, Oct. 23, 2025 /PRNewswire/ — Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering therapies that target the root causes of inflammation-driven diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its investigational medicine ofirnoflast (HT-6184) for the treatment of Myelodysplastic Syndromes (MDS) — a group of bone marrow disorders characterized by ineffective blood cell production and a risk of progression to acute myeloid leukemia (AML).

The FDA grants Orphan Drug Designation to therapies intended for the treatment, prevention, or diagnosis of rare diseases or conditions that affect fewer than 200,000 people in the United States at the time of designation.

“This designation underscores the potential of our approach in Myelodysplastic Syndromes and supports our commitment to developing new treatment options for patients living with MDS,” said David Bearss, PhD, Chief Executive Officer of Halia Therapeutics. “Ofirnoflast represents a first-in-class approach to modulating inflammasome biology, an upstream driver of inflammation, with the goal of restoring healthy bone marrow function.”

Ofirnoflast is a selective NEK7 allosteric modulator designed to prevent the formation and promote the disassembly of the NLRP3 inflammasome, a central driver of chronic inflammation in multiple diseases. In MDS, inflammasome activation is increasingly recognized as a key contributor to ineffective hematopoiesis and bone marrow failure. By modulating NEK7, ofirnoflast aims to restore immune balance and improve blood-cell production without broad immunosuppression.

“Inflammasome biology represents a promising frontier for hematologic innovation,” said Alan F. List, MD, member of Halia Therapeutics’ Scientific Advisory Board and former President and CEO of Moffitt Cancer Center. “Ofirnoflast’s approach is distinctive in that it seeks to modulate the underlying inflammatory drivers of MDS rather than just its downstream effects. This strategy has the potential to redefine how inflammation-linked bone marrow failure is treated.”

Under the FDA’s Orphan Drug Act, orphan-drug status provides several incentives, including tax credits for qualified clinical testing, exemption from FDA user fees, and potential for seven years of U.S. market exclusivity upon approval. The FDA also administers grant programs to support clinical research and advance the development of therapies for rare diseases.

About Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes are a group of bone marrow disorders characterized by defective blood-cell formation, leading to anemia, infection risk, and bleeding complications. MDS primarily affects older adults and can progress to acute myeloid leukemia (AML). Current therapies, including hypomethylating agents and growth factors, often provide limited benefit and do not address the underlying inflammatory biology of the disease.

About Ofirnoflast (HT-6184)

Ofirnoflast (HT-6184) is Halia Therapeutics’ lead investigational compound and a first-in-class NEK7 modulator that regulates activation of the NLRP3 inflammasome — an upstream molecular complex involved in chronic inflammation. The drug is currently being evaluated across multiple disease areas, including:

• Myelodysplastic Syndromes (MDS) – completed Phase 2 study evaluating safety and hematologic outcomes
• Obesity (in combination with semaglutide) – ongoing Phase 2 study targeting adipose inflammation and metabolic dysregulation
• Alzheimer’s Disease – early-stage program focused on genetically at-risk populations

About Halia Therapeutics, Inc.

Halia Therapeutics is a clinical-stage biopharmaceutical company developing therapies that leverage genetic resilience to restore the body’s natural ability to resolve inflammation. By targeting the NEK7–NLRP3 inflammasome axis, Halia’s pipeline addresses a spectrum of chronic inflammatory and degenerative diseases, including hematologic disorders, metabolic disease, and neurodegeneration.

To learn more, visit www.haliatx.com or follow Halia Therapeutics on LinkedIn and X (Twitter).

Media Contact:
Taylor Avei
Director, Business Development
Halia Therapeutics, Inc.
info@haliatx.com
+1 (385) 355-4315

Leigh Salvo 
New Street Investor Relations
leigh@newstreetir.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about the potential therapeutic benefits of ofirnoflast, the company’s clinical development plans, regulatory strategies, and commercial opportunities. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks include uncertainties related to clinical trial results, regulatory approval processes, competitive developments, and the company’s ability to secure adequate funding for continued operations. Halia Therapeutics undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

NEW YORK, Oct. 23, 2025 /PRNewswire/ — The past 12 months have been erratic for the Wi-Fi equipment industry. While shipments remained sluggish in the second half of 2024, there was a growing sense of optimism for 2025, with a feeling that the turbulence and uncertainty that had plagued the industry since 2020 had finally been replaced by stability and predictability. The industry was reassured that the periodic equipment refresh cycles of Internet Service Providers (ISP) and enterprises were back on track, and the gradual acceleration of Wi-Fi 7 was expected to provide sustained momentum in the market. However, these assumptions were quickly upended in the first half of 2025. Tariff threats and a breakdown of established trading relations reintroduced unpredictability into the market. In the short term, this led to a dramatic surge in shipments as purchasers accelerated orders to get ahead of tariffs. This was particularly pronounced in North America, where tariff threats coincided with planned Wi-Fi 7 deployments by major tier 1 US ISPs, including AT&T and Comcast. Reflecting this, global technology intelligence firm ABI Research recorded that total shipments of Wi-Fi equipment into the North American market jumped 38.3% quarter-over-quarter (QoQ) in the second quarter of 2025.

“While many are delighted by the shipment spike in 1H 2025, celebrations may be short-lived because much of the expansion was driven by pulled-forward demand rather than the creation of new demand,” said Andrew Spivey, Principal Analyst at ABI Research. “Furthermore, the potential for additional unanticipated tariffs or trade restrictions continues to loom ominously in the background, creating a sense of general economic uncertainty which will plague the market going forward.”

Toward the end of the decade, the introduction of Wi-Fi 8 is expected to deliver another major boost to the market. Early prototypes are anticipated next year, with annual shipments projected to rise from just over 0.4 million pre-standard units in 2027 to 81.4 million by 2030. Unlike earlier Wi-Fi generations, which emphasized faster throughputs, Wi-Fi 8 is designed to achieve “Ultra High-Reliability.” While this shift will enhance user experiences, reliability gains are more difficult to communicate than simple speed metrics. As a result, the value proposition may be less compelling to ISPs, which have traditionally focused on data rates.

“In order for Wi-Fi 8 to gain strong adoption by consumers and enterprises, the Wi-Fi industry will need to completely reorientate their go-to-market strategies for the technology,” Spivey continues. “This will involve creating clear and transparent benchmarks which consumers can use to measure Wi-Fi 8’s promised reliability gains and devising methods to successfully promote the Multi-Access Point Coordination feature.”

These findings are from ABI Research’s Residential, Enterprise, and Industrial WLAN Markets and Technologies Market Dataset, part of the company’s Wi-Fi & WLAN Technologies & Markets research service, which includes research, data, and analyst insights. Based on extensive primary interviews, market data reports present in-depth analysis of key market trends and factors for a specific technology.

About ABI Research

ABI Research is a global technology intelligence firm uniquely positioned at the intersection of technology solution providers and end-market companies. We serve as the bridge that seamlessly connects these two segments by providing exclusive research and expert guidance to drive successful technology implementations and deliver strategies proven to attract and retain customers.

ABI Research是一家全球性的技术情报公司，拥有得天独厚的优势，充当终端市场公司和技术解决方案提供商之间的桥梁，通过提供独家研究和专业性指导，推动成功的技术实施和提供经证明可吸引和留住客户的战略，无缝连接这两大主体。

For more information about ABI Research’s services, contact us at +1.516.624.2500 in the Americas, +44.203.326.0140 in Europe, +65.6592.0290 in Asia-Pacific, or visit www.abiresearch.com.

Contact Info:

Global                                        
Jason Scheer
Tel: +1.516.624.2558                                         
pr@abiresearch.com